You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Multiplexed Biofiltration of Volatile Organic Compounds

    SBC: WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY LLC            Topic: ST16C001

    Volatile organic compounds (VOCs) in air, especially in closed environments pose a major health threat. There is a critical need to remove these pollutant, and biofiltration is a promising solution to this need. This is a Phase II STTR proposal is to develop a novel, modular and scalable approach to biofiltration for effective management of air pollutants in closed environments. We propose a novel ...

    STTR Phase II 2018 Department of DefenseDefense Advanced Research Projects Agency
  4. Brain penetrant Hsp90 inhibitors for Alzheimer's disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION provided by applicant Neurodegeneration in Alzheimerandapos s disease AD may result from deposition of A as plaques in brain tissue However less effort has been made to elucidate the role of tau containing neurofibrillary tangles NFTs in AD Accumulating evidence suggests that tau containing NFTs is an important component in the initiation and progression of AD and other neu ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Advancing a novel portable detection method for cannabis intoxication

    SBC: Brain Solutions, LLC            Topic: NIDA

    TBD

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Cloud quantitative imaging for whole-body tumor burden in neurofibromatoses

    SBC: IQ MEDICAL IMAGING LLC            Topic: 102

    Project SummaryAbstract The neurofibromatosesNFsincluding NFNFand schwannomatosisare a group of autosomal dominant neurogenetic disorders characterized by a predisposition in virtuallyof patients to develop multiple nerve sheath tumorsThe determination of tumor burden on magnetic resonance imagingMRIis indispensable for the longitudinal management of NF patientswhich includes life long follow up f ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Extending Genome-Phenome Analysis

    SBC: SimulConsult, Inc.            Topic: 172

    DESCRIPTION provided by applicant The declining cost of whole exome sequencing WES is nearing the point at which the spread of WES into clinical practice will be limited largely by the cost of interpreting the results and comparing them to the patientandapos s clinical findings This project builds on our demonstrated capability to reduce this interpretation cost by pairing our diagnostic sof ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Emergency Operations Plans for Individuals with Disabilities

    SBC: PRAXIS, INC.            Topic: NICHD

    DESCRIPTION provided by applicant The proposed project is designed to fill an important yet unmet need by developing an online education program using simulations and scenario based learning to reach all public health and safety emergency responders and students responsible for emergency planning with and response for individuals with disabilities In Phase II the applicant organization P ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. MDCT Quantification of hepatic tumor viability for assessment of cancer therapy

    SBC: IQ MEDICAL IMAGING LLC            Topic: 102

    Project SummaryAbstract Tumor imaging quantification is critical for diagnosisstagingand treatment evaluationand multi detector CTMDCTis the clinical imaging modality commonly used for patients diagnosed with hepatic malignancy because of its relatively low cost and wide availabilityConventional tumor quantification using either linear or volumetric measurement has demonstrated significant limitat ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government